Skip to main content
Beijing Kawin Technology Share-Holding Co., Ltd. logo

Beijing Kawin Technology Share-Holding Co., Ltd. — Investor Relations & Filings

Ticker · 688687 ISIN · CNE1000054C3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2026-05-06 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688687

About Beijing Kawin Technology Share-Holding Co., Ltd.

https://www.kawin.com.cn/

Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical enterprise focused on the research, development, and commercialization of innovative therapeutic solutions. The company specializes in the treatment of viral infections, particularly chronic hepatitis C, as well as oncology and immunological disorders. Its product portfolio includes recombinant human interferon α2b, ribavirin, and advanced direct-acting antiviral (DAA) therapies. Kawin Technology leverages integrated platforms for protein engineering and chemical drug synthesis to address unmet medical needs. The firm maintains a comprehensive value chain encompassing drug discovery, clinical development, and large-scale manufacturing. By prioritizing scientific innovation, the company aims to provide high-quality, accessible treatments for complex diseases, establishing a significant presence in the specialized pharmaceutical market.

Recent filings

Filing Released Lang Actions
凯因科技2025年年度股东会会议资料
AGM Information Classification · 100% confidence The document is titled as "2025年年度股东会会议资料" which translates to "2025 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, reports to be presented at the AGM, proposals for shareholder approval, and other materials typically distributed to shareholders before or during an AGM. The content includes the board's work report, profit distribution plan, remuneration proposals, audit firm reappointment, and independent directors' reports, all of which are standard AGM materials. The document is lengthy (over 12,000 characters) and contains the full meeting materials, not just an announcement or a brief summary. Therefore, it fits the category of AGM Information (AGM-R).
2026-05-06 Chinese
凯因科技关于参加十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度生物制品行业集体业绩说明会暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an upcoming investor performance explanation meeting (业绩说明会) for the 2025 annual results and 2026 Q1 results. It provides details about the meeting time, location, participants, and how investors can join and ask questions. It references that the company has already published the 2025 annual report and 2026 Q1 report on April 25, 2026, but this document itself does not contain any financial data or detailed results. It is essentially a notice about the investor presentation event rather than the presentation or report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or notice. Given the detailed meeting information and focus on investor communication, the classification is Investor Presentation (IP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear meeting and investor presentation context.
2026-05-06 Chinese
凯因科技2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案
Regulatory Filings Classification · 35% confidence The document is a standalone “Action Plan Evaluation Report” covering the company’s execution of its 2025 action plan and laying out its 2026 plan. It is not an AGM presentation, annual or interim financial report, earnings release, call transcript, or any other narrowly defined filing. It is a general corporate report on governance, investor returns, R&D, and future strategy, which does not fit any specific category. Therefore, it falls into the fallback category of miscellaneous regulatory announcement.
2026-04-24 Chinese
凯因科技2025年度独立董事述职报告（杜臣）
Governance Information Classification · 85% confidence The document is titled “2025年度独立董事述职报告” and consists of an independent director’s annual work report, detailing governance processes, board/committee activities, attendance, compliance with laws and listing rules, and recommendations. It is not a financial report, capital notice, or management change announcement, but a corporate governance disclosure. This aligns with the Governance Information category (CGR).
2026-04-24 Chinese
凯因科技关于公司使用部分闲置自有资金购买理财产品的公告
Regulatory Filings Classification · 85% confidence The document is a board‐approved public announcement detailing the company’s use of idle self‐owned funds to purchase financial products. It does not report financial results (ER/IR/10-K), dividend (DIV), share issues (SHA), share repurchases (POS), major shareholdings (MRQ), legal matters (LTR), M&A (TAR), or other specific transactions. It is not a report itself but a standalone regulatory announcement of a corporate transaction/decision. This fits the fallback category “Regulatory Filings” (RNS).
2026-04-24 Chinese
凯因科技2025年度董事会审计委员会履职情况报告
Governance Information Classification · 72% confidence The document is a standalone “2025年度董事会审计委员会履职情况报告” (2025 Annual Board Audit Committee Performance Report) filed by Beijing KAIN Technology. It is not an earnings release, dividend announcement, share issuance notice, or regulatory delisting. It is a detailed report on the audit committee’s membership, meeting activities, oversight of internal/external audits, and governance processes—i.e., a governance‐related document. Therefore, it best fits the Governance Information category (CGR).
2026-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.